Medtronic Diabetes Appoints Dexcom Veteran Laura Endres as New Americas Lead Amid IPO Preparations

Recently, Medtronic officially announced that Laura Endres, former senior executive of Dexcom, will take on the role as the new head of its Diabetes Business in the Americas.

Laura Endres, the newly appointed head of Medtronic's Diabetes Business in the Americas

Laura Endres Shared Her Joy and Expectations of Joining Medtronic on LinkedIn. In her post, she revealed that last week was her first week officially joining Medtronic's Diabetes Division.

Looking back on his career, Endres was deeply involved in Dexcom, a leader in the continuous glucose monitoring (CGM) field.Farming for up to 14 years, with outstanding leadership skills and keen market insight,She has advanced to the position of Senior Vice President of North America Channels, accumulating extensive experience across the entire diabetes industry chain. Prior to this, she worked at Johnson & Johnson for 12 years.

For her new role, Endres is full of confidence and enthusiasm: "I am delighted to join Medtronic. Just one week into the job, I have already felt the vibrancy and boundless ambition of this team. They are eager to push boundaries and create brilliant results for Medtronic's Diabetes Business; even more, they are passionate about delivering tangible value to every customer through professional service. I firmly believe that with this united, driven, and passionate team, we will undoubtedly achieve remarkable success."

Nihal Singh, Vice President of Medtronic Diabetes U.S. Field Sales and Clinical, also extended his warm congratulations on LinkedIn regarding the appointment, calling it "exciting news."

Singh spoke highly of Endres' professional capabilities and industry influence: "Laura has deep积累 in the medical technology and diabetes sectors, and her work experience at Dexcom has given her a unique perspective on the industry."Her joining will undoubtedly inject strong momentum into Medtronic's diabetes business."Under her outstanding leadership, our passionate team is bound to surpass existing achievements, reach new milestones, and drive transformative changes with profound impact in the field of diabetes treatment."

It is worth mentioning that,Endres joins Medtronic at a critical time when the company is actively expanding and seeking breakthroughs in diabetes technology.

In recent years, Medtronic has continuously increased its investment in diabetes technology research and development, committing to provide more advanced and effective treatment solutions for diabetic patients worldwide. Currently, the company is actively promoting the application of automated insulin delivery technology in the field of type 2 diabetes treatment.

At the same time, Medtronic is actively developing the next generation of insulin pumps. Through strategic cooperation with medical technology giants such as Abbott, it integrates the superior resources of all parties to accelerate the research and development and market launch of innovative products.

In the future, we look forward to seeing Medtronic continuously break through innovations under the leadership of Laura Endres, bringing more good news to diabetes patients and pushing the global diabetes treatment cause to new heights.